目的 評(píng)價(jià)癃清片聯(lián)合化學(xué)藥治療III型前列腺炎［即慢性前列腺炎/慢性盆腔疼痛綜合征（CP/CPPS）］的療效及安全性。方法 檢索PubMed、Embase、Medline、Web of Science、Cochrane Library、中國(guó)學(xué)術(shù)期刊全文數(shù)據(jù)庫(kù)（CNKI）、萬(wàn)方數(shù)據(jù)知識(shí)服務(wù)平臺(tái)（Wanfang Data）、維普中文科技期刊數(shù)據(jù)庫(kù)（VIP）、中國(guó)生物醫(yī)學(xué)文獻(xiàn)服務(wù)系統(tǒng)（SinoMed）等數(shù)據(jù)庫(kù)自建庫(kù)至2022年1月關(guān)于癃清片治療CP/CPPS的臨床隨機(jī)對(duì)照試驗(yàn)（RCT），根據(jù)納排標(biāo)準(zhǔn)篩選文獻(xiàn)，并采用Revman 5.4軟件進(jìn)行Meta分析。結(jié)果 共納入8項(xiàng)RCTs，共計(jì)1 000例患者，其中試驗(yàn)組503例、對(duì)照組497例。Meta分析結(jié)果顯示治療后試驗(yàn)組美國(guó)國(guó)立衛(wèi)生院慢性前列腺炎癥狀評(píng)分癥狀總分［MD=?2.65，95% CI（?3.28，?2.03），P＜0.000 01］、疼痛癥狀評(píng)分［MD=?1.44，95% CI（?1.95，?0.92），P＜0.000 01］、生活質(zhì)量評(píng)分［MD=?0.50，95% CI（?0.93，?0.06），P=0.03］均低于對(duì)照組；排尿癥狀評(píng)分與對(duì)照組比較差異不顯著［MD=?0.17，95% CI（?0.85，0.50），P=0.61］，敏感性分析顯示對(duì)照組干預(yù)措施僅應(yīng)用1種化學(xué)藥，則差異具有統(tǒng)計(jì)學(xué)意義［MD=?0.75，95% CI（?1.43，?0.07），P=0.03］；前列腺按摩液中白細(xì)胞計(jì)數(shù)低于對(duì)照組［MD=?4.33，95% CI（?6.59，?2.08），P=0.002］；不良反應(yīng)發(fā)生率與對(duì)照組比較差異不顯著［RR=1.00，95% CI（0.46，2.19），P=0.99］。結(jié)論 癃清片能顯著改善CP/CPPS患者癥狀，降低前列腺按摩液中白細(xì)胞數(shù)量，且不會(huì)顯著增加不良反應(yīng)的發(fā)生。

Objective To evaluate the efficacy and safety of Longqing Tablet combined with pharmaceutical chemicals in the treatment of type III prostatitis, which is chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Methods Data were electronically searched from the PubMed, Embase, Medline, Web of Science, Cochrane Library, CNKI, Wanfang Data, VIP, and SinoMed to collet randomized controlled trails (RCTs) on Longqing Tablet in the treatment of CP/CPPS. The retrieval time was from database establishment to January 2022. The literatures were screening according to inclusion criteria and exclusion criteria. The Meta-analysis was carried out by Revman 5.4 software. Results A total of eight RCTs were selected, including 1 000 cases (503 cases in the experimental group and 497 cases in the control group). Meta-analysis showed that the NIH-CPSI symptom score (total score) is lower than that of the control group [MD = -2.65, 95%CI (-3.28, -2.03), P<0.000 01]. The pain symptom score is lower than that of the control group [MD = -1.44, 95%CI (-1.95, -0.92), P<0.000 01]. The quality of life score is lower than that of the control group [MD = - 0.50, 95%CI (- 0.93, - 0.06), P=0.03]. There are no significant differences in voiding symptom score between control group and control group [MD=-0.17, 95%CI (-0.85, 0.50), P=0.61], but there are significant differences between experimental group and control group when only use one pharmaceutical chemical in the control group [MD=-0.75,95%CI (-1.43, -0.07), P = 0.03]. The EPS leukocyte count is lower than that of the control group [MD=-4.33,95%CI (-6.59, -2.08), P=0.002]. Finally, there is no significant difference in adverse reaction rate compared with the control group [RR = 1.00, 95%CI (0.46, 2.19), P=0.99]. Conclusion Longqing Tablet can improve the symptoms and reduce leukocyte count of EPS in CP/CPPS patients significantly. Moreover, it do not increase the incidence of adverse reactions significantly.

R287.3

中國(guó)中醫(yī)科學(xué)院科技創(chuàng)新工程項(xiàng)目(CI2021A00905);中國(guó)中醫(yī)科學(xué)院基本業(yè)務(wù)費(fèi)自主選題項(xiàng)目(Z0546)